Simplex Trading’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.73M Sell
44,600
-106,100
-70% -$3.71M ﹤0.01% 2197
2026
Q1
$5.8M Buy
150,700
+82,100
+120% +$3.03M ﹤0.01% 1013
2025
Q4
$2.44M Buy
68,600
+5,400
+9% +$152K ﹤0.01% 1819
2025
Q3
$907K Buy
63,200
+17,300
+38% +$205K ﹤0.01% 3156
2025
Q2
$329K Buy
+45,900
New +$254K ﹤0.01% 3965
2025
Q1
Sell
-47,100
Closed -$367K 8647
2024
Q4
$367K Sell
47,100
-1,000
-2% -$9.97K ﹤0.01% 3856
2024
Q3
$519K Sell
48,100
-4,600
-9% -$44.8K ﹤0.01% 3548
2024
Q2
$444K Buy
52,700
+22,400
+74% +$170K ﹤0.01% 3793
2024
Q1
$203K Buy
+30,300
New +$187K ﹤0.01% 4839
2023
Q4
Sell
-4,500
Closed -$43K 8902
2023
Q3
$43K Buy
4,500
+4,400
+4,400% +$52.2K ﹤0.01% 5940
2023
Q2
$1K Sell
100
-1,200
-92% -$13.8K ﹤0.01% 8587
2023
Q1
$14K Buy
+1,300
New +$16.6K ﹤0.01% 7237
2022
Q4
Sell
-100
Closed -$1K 9337
2022
Q3
$1K Sell
100
-57,300
-100% -$785K ﹤0.01% 9499
2022
Q2
$517K Buy
+57,400
New +$392K ﹤0.01% 3397

Other funds holding COGT

Simplex Trading's COGT Position: Q2 2026 in Review

Simplex Trading reduced its Cogent Biosciences (COGT) stake by 91% in Q2 2026, selling an estimated $101K and leaving 277 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #7646.

Simplex Trading first reported a position in COGT in Q4 2021 and has held it in 12 quarters since. The position peaked at $961K in Q3 2025. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Simplex Trading held 277 shares of Cogent Biosciences worth $10.7K as of Q2 2026.
  • Simplex Trading sold 2,876 Cogent Biosciences shares in Q2 2026, an estimated $101K.
  • Cogent Biosciences made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7646 holding.
  • Simplex Trading first reported a position in Cogent Biosciences in Q4 2021 and has held it in 12 quarters since.
  • Simplex Trading's Cogent Biosciences position peaked at $961K in Q3 2025.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.